Staging of renal cell carcinoma: current progress and potential advances.

Renal cell carcinoma Tumour Nodes Metastases Union Internationale Contre le Cancer peri-renal fat prognosis renal sinus invasion staging

Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 26 08 2020
accepted: 30 08 2020
pubmed: 31 10 2020
medline: 5 10 2021
entrez: 30 10 2020
Statut: ppublish

Résumé

Formal staging classifications for renal cell carcinoma (RCC) were first proposed in 1978 and were incorporated into the Tumour, Nodes, Metastases (TNM) system initially published by the Union Internationale Contre le Cancer (UICC) in 1978. There has been a gradual evolution of grading criteria through six separate editions of the UICC TNM Classification, with the latest edition being published in 2016. Somewhat surprisingly there were no changes to the T category criteria from the 2009 to the 2016 editions of the classification, although an erratum has subsequently been published that incorporated the minor changes included in the eighth edition of the TNM Classification published by the American Joint Committee on Cancer. Localised tumours are staged according to the size of the primary tumour, with the TNM classification recognising that these tumours may exceed 10 cm in diameter. This is unfortunate as there is good evidence to demonstrate that, for clear cell RCC, virtually all tumours >7 cm in diameter and a substantial proportion of tumours <7 cm in diameter, show extra-renal spread. Infiltration of tumour beyond the renal capsule into the peri-renal fat is also categorised as T3a, however the clinical importance of this remains unclear. The classification of microvascular invasion within the renal sinus requires clarification, as does the prognostic significance of tumour in small vessels within the kidney.

Identifiants

pubmed: 33121821
pii: S0031-3025(20)30930-2
doi: 10.1016/j.pathol.2020.08.007
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-128

Informations de copyright

Copyright © 2020 Royal College of Pathologists of Australasia. All rights reserved.

Auteurs

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.

John N Eble (JN)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.

Hemamali Samaratunga (H)

Aquesta Uropathology and University of Queensland, Brisbane, Qld, Australia.

Michelle Thunders (M)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

John W Yaxley (JW)

Department of Medicine, University of Queensland, Wesley Urology Clinic, Royal Brisbane and Womens Hospital, Brisbane, Qld, Australia.

Lars Egevad (L)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH